Send to

Choose Destination
Onco Targets Ther. 2018 Aug 30;11:5287-5291. doi: 10.2147/OTT.S170008. eCollection 2018.

Successful treatment of relapsed testicular embryonal rhabdomyosarcoma with Endostar and traditional chemotherapy: a case report.

Author information

Department of Oncology, Cancer Center of People's Liberation Army, General Hospital of Shenyang Military Region, Shenyang 110840, People's Republic of China,
Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110840, People's Republic of China.
Department of Pathology, General Hospital of Shenyang Military Region, Shenyang 110840, People's Republic of China.


Embryonal rhabdomyosarcoma (ERMS) has a low prevalence, poor prognosis, and limited treatment efficacy. We report a case of an 18-year-old male whose disease relapsed in the abdominal cavity after a testicular ERMS curative resection. The patient received eight sequential cycles of rescue therapy using cisplatin and isocyclophosphamide in combination with a vascular targeted drug, Endostar. The therapeutic effect of the combination regimen has been evaluated for complete response. This is the first case to report using Endostar and chemotherapy in relapsed ERMS, and the curative effect results in complete response. Endostar, a new vascular targeted drug, combined with chemotherapy may play a synergistic role and provide a reference for the treatment of ERMS.


complete response; embryonal rhabdomyosarcoma; endogenous angiogenesis inhibitor; metastasis

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center